Liu Guozheng, Hnatowich Donald J
Division of Nuclear Medicine, Department of Radiology, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Anticancer Agents Med Chem. 2007 May;7(3):367-77. doi: 10.2174/187152007780618144.
For radiotherapy, biomolecules such as intact antibodies, antibody fragments, peptides, DNAs and other oligomers have all been labeled with radiorhenium ((186)Re and (188)Re). Three different approaches have been employed that may be referred to as direct, indirect and integral labeling. Direct labeling applies to proteins and involves the initial reduction of endogenous disulfide bridges to provide chelation sites. Indirect labeling can apply to most biomolecules and involves the initial attachment of an exogenous chelator. Finally, integral labeling is a special case applying only to small molecules in which the metallic radionuclide serves to link two parts of a biomolecule together in forming the labeled complex. While the number of varieties for the direct and integral radiolabeling approaches is rather limited, a fairly large and diverse number of chelators have been reported in the case of indirect labeling. Our objective herein is to provide an overview of the various chelators that have been used in the indirect labeling of biomolecules with radiorhenium, including details on the labeling procedures, the stability of the radiolabel and, where possible, the influence of the label on biological properties.
对于放射治疗,完整抗体、抗体片段、肽、DNA和其他低聚物等生物分子都已用放射性铼((186)Re和(188)Re)进行标记。已采用三种不同的方法,可称为直接标记、间接标记和整体标记。直接标记适用于蛋白质,涉及将内源性二硫键初步还原以提供螯合位点。间接标记可适用于大多数生物分子,涉及最初连接外源性螯合剂。最后,整体标记是仅适用于小分子的一种特殊情况,其中金属放射性核素在形成标记复合物时用于将生物分子的两个部分连接在一起。虽然直接和整体放射性标记方法的种类相当有限,但在间接标记的情况下已报道了相当多且多样的螯合剂。我们在此的目的是概述已用于生物分子与放射性铼间接标记的各种螯合剂,包括标记程序的细节、放射性标记的稳定性,并在可能的情况下,标记对生物学特性的影响。